VitaSpring Biomedical Co. Ltd.

VSBC

US92851B1026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 19:03:41 11/08/2023 BST			5-day change	1st Jan Change
15 ^USD	+36.24%		-.--%	-.--%

2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI

VitaSpring Biomedical Co. Ltd. has completed an IPO.

December 04, 2017 at 05:00 am

VitaSpring Biomedical Co. Ltd. has completed an IPO. Security Name: Common Stock Security Type: Common Stock PriceRange: $0.03 Discount Per Security: $0

Latest news about VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	21/12/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	15/09/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2022	15/06/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2022	03/05/22	CI
VitaSpring Biomedical Co. Ltd. Auditor Raises 'Going Concern' Doubt	02/05/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	23/12/21	CI
QuantuMDx Group Limited announced that it has received ?15 million in funding from VitaSpring Biomedical Co. Ltd.	06/11/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2021	15/09/21	CI
Vitaspring Biomedical Co. Ltd. Announces Management Changes	11/08/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2021	14/06/21	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2021	14/04/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter Ended October 31, 2020	15/12/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2020	28/09/20	CI
VitaSpring Biomedical Co. Ltd. announced that it expects to receive $0.082342 million in funding	13/07/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2020	19/06/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2020	09/06/20	CI
SHEMN CORP will Change its Name to VitaSpring Biomedical Co. Ltd	21/04/20	CI
VitaSpring Biomedical Co. Ltd. will Change its Ticker to VSBC from SHNC	21/04/20	CI
Shemn Corp. Announces Management Changes	26/02/20	CI
Shemn Corp. Announces Management Changes	31/01/20	CI
Shemn Corp. Reports Earnings Results for the Third Quarter Ended October 31, 2019	12/12/19	CI
Shemn Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2019	27/08/19	CI
Shemn Corp. Reports Earnings Results for the First Quarter Ended April 30, 2019	03/06/19	CI
Shemn Corp. Announces Executive Changes	17/04/19	CI
VitaSpring Biomedical Co. Ltd. has completed an IPO.	04/12/17	CI

Chart VitaSpring Biomedical Co. Ltd.

Duration

Period

More charts

Vitaspring Biomedical Co. Ltd. is focused on cell medical industry. The Company is engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle. The Company invests in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and cell production centers and provides GTP standard stem cell preparations for the development of cellular drugs. The Company is focused on the fields of medicine, preventive health care, beauty, and anti-aging. It is also focused on developing X.MSC cytopharmaceuticals.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VITASPRING BIOMEDICAL CO. LTD.	-.--%	3.11B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs